« Return to News | Clinical Intelligence

Pinpoint Genomics publishes Dx Lung assay data

Tuesday, January 31, 2012 09:38 AM

Pinpoint Genomics has published key data relating to its Pinpoint Dx Lung assay in the journal The Lancet, and has made the assay available to clinicians and patients exclusively through the company's laboratory in Mountain View, Calif.

The Pinpoint Dx Lung assay is a molecular diagnostic assay that differentiates between patients at high, intermediate or low risk of early death after surgery to remove a non-squamous, non-small cell lung cancer, the most common form of lung cancer, in patients with early-stage disease.

The report in The Lancet describes the development of the assay based on specimens from 361 patients who underwent surgery at the University of California, San Francisco (UCSF). The assay was also based on results from the two largest independent, blinded studies to evaluate the clinical validity of a multi-gene molecular diagnostic assay for early-stage lung cancer, conducted by the Kaiser Permanente division of research—involving 433 patients—and the China Clinical Trials Consortium—a total of 1,006 patients from several leading cancer centers in China.

The Pinpoint Dx Lung assay is run on surgical specimens that undergo routine handling by pathology laboratories, making it immediately available to virtually all patients, and is offered through Pinpoint's Clinical Laboratory Improvement Amendment-certified laboratory.

Share:          
CWWeekly

May 21

Parexel consultant testifies on FDA biosimilars guidance

Global Telecom Testing checks ex-U.S. toll-free phone lines for multinational clinical trials

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

May

Newer sites most optimistic about the future
Investigative sites of all sizes, from part-time physician-run sites to large dedicated research centers, report a rebound in operating conditions, according to a new CenterWatch analysis, yet sites from each subgroup indicate they have concerns…

Risk-based monitoring slow to catch on with industry
It's estimated that the cost of physically sending monitors to all investigative sites at regular intervals, a model the industry itself developed and has adhered to for about a decade, eats up one-third to one-half of…

Eye On Millennium
Millennium, The Takeda Oncology Company, discovers and develops novel treatments applying world-class recombinant technology to a wide variety of oncology disease targets…

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

Copyright © 1995-2012 CenterWatch.